| 02.02.22 | VCs infuse $215M into Sanofi-backed startup; Ex-Genzyme exec in subcut SPAC merger

Laden...

2 jaren geleden

Html
Tekst

Webinar: Formulation Strategies: Moving IV to SQ & Vial to PFS

Wednesday, February 16 | 9am ET / 6am PT / 3pm CET

Improving patient compliance is a goal for many biopharma companies. Learn more about strategies when formulating subcutaneous administration and prefilled syringe presentation in this webinar. Register now.

Today's Rundown

VCs infuse $215M into Sanofi-backed wearable subcutaneous drug delivery player Enable Injections Sherblom's Comera inks SPAC merger to fund subcutaneous delivery programs Stevanato doubles down on pen injector technology, expanding into indications beyond diabetes West and Corning team up for injectable drug delivery project Roche, with an FDA nod for Vabysmo in hand, looks to challenge Regeneron's dominant Eylea

Featured Story

VCs infuse $215M into Sanofi-backed wearable subcutaneous drug delivery player Enable Injections

By Nick Paul Taylor

Sanofi-backed Enable Injections has gone big with its series C round. Three years after Sanofi led its series B, Enable Injections has raised a $215 million round to fund work on subcutaneous drug delivery system enFuse.

This week's sponsor is CPC.

Sherblom's Comera inks SPAC merger to fund subcutaneous delivery programs

By Nick Paul Taylor

Jim Sherblom’s Comera Life Sciences has inked a SPAC merger. The subcutaneous delivery specialist is set to generate around $107 million through the deal to fund work on partnerships and internal programs.

Stevanato doubles down on pen injector technology, expanding into indications beyond diabetes

By Nick Paul Taylor

Stevanato is doubling down on Haselmeier’s Axis-D pen injector technology. Having originally licensed the delivery technology in diabetes, Stevanato has now bagged the rights to use it across a wide range of therapeutic areas.

West and Corning team up for injectable drug delivery project

By Nick Paul Taylor

West Pharmaceutical Services is hooking up with Corning. As part of an exclusive long-term deal, West is making a multimillion-dollar capital and R&D investment in its new partner to advance drug delivery.

Roche, with an FDA nod for Vabysmo in hand, looks to challenge Regeneron's dominant Eylea

By Kevin Dunleavy

With an FDA approval for Vabysmo to treat wet-age related macular degeneration (AMD) and diabetic macular edema (DME), Genentech and Roche have an antibody drug that could challenge Regeneron and Bayer's Eylea. The key edge for Vabysmo is that for most patients, it would allow fewer injections.

Webinar: Escape from HPLC. Excipient Compatibility by Differential Scanning Calorimetry (DSC)/ Modulated DSC (MDSC).

Monday, February 28, 2022 | 10 am ET / 7am PT

The pharmaceutical industry traditionally tests excipient compatibility by incubating binary mixtures of API and excipient at stress conditions and testing over time by HPLC. These tests take up to 3 months to complete, slowing the progress of formulation development. DSC/MDSC analysis is a better technique over HPLC as it is faster, can detect chemical and physical changes, and is more ecofriendly using less materials. Register now.